Revised forecast
Fiscal year ending December 2026 · Full yearThe bar length represents the relative magnitude of change, based on the item that changed the most in this document.
The forecast had not been disclosed because it was difficult to reasonably calculate revenue and other figures while negotiations for a sales partnership for Bondlido were ongoing. The company has now released the forecast because, based on certain assumptions, it has become possible to estimate the impact of the start of sales on results for the current fiscal year. Research and development expenses are expected to increase by ¥401 million from the previous fiscal year due to costs related to the Phase 2 trial of MRX-4TZT, while selling, general and administrative expenses excluding research and development expenses are expected to increase by ¥138 million from the previous fiscal year due to costs including those for maintaining Bondlido's marketing approval.
| Item | Details |
|---|---|
| Net Sales | Not disclosed → ¥507 million（+296.4%） |
| Operating profit | Not disclosed → ¥-1,472 million |
| Ordinary income | Not disclosed → ¥-1,472 million |
| Profit attributable to owners of the parent | Not disclosed → ¥-1,502 million |
| Net income per share | Not disclosed → -25.30 yen and sen |
| Fiscal Period Covered | Fiscal year ending December 2026 |
| Period Covered | Full year |
| Previous-period results | Revenue: ¥128 million; operating profit: ¥941 million loss; ordinary profit: ¥937 million loss; net income attributable to owners of the parent: ¥937 million loss; net income per share: ¥17.44 loss |
| Reason for the revision | The forecast had not been disclosed because it was difficult to reasonably calculate revenue and other figures while negotiations for a sales partnership for Bondlido were ongoing. The company has now released the forecast because, based on certain assumptions, it has become possible to estimate the impact of the start of sales on results for the current fiscal year. Research and development expenses are expected to increase by ¥401 million from the previous fiscal year due to costs related to the Phase 2 trial of MRX-4TZT, while selling, general and administrative expenses excluding research and development expenses are expected to increase by ¥138 million from the previous fiscal year due to costs including those for maintaining Bondlido's marketing approval. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (3)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The forecast had not been disclosed because it was difficult to reasonably calculate revenue and other figures while negotiations for a sales partnership for Bondlido were ongoing. The company has now released the forecast because, based on certain assumptions, it has become possible to estimate the impact of the start of sales on results for the current fiscal year. On the cost side, research and development expenses are expected to increase by ¥401 million due to costs related to the Phase 2 trial of MRX-4TZT, while selling, general and administrative expenses excluding research and development expenses are expected to increase by ¥138 million due to costs including those for maintaining Bondlido's marketing approval.